Bafna Pharmaceuticals Limited - Asset Resilience Ratio

Latest as of September 2025: 1.07%

Bafna Pharmaceuticals Limited (BAFNAPH) has an Asset Resilience Ratio of 1.07% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

Rs17.13 Million

≈ $185.21K USD Cash + Short-term Investments

Total Assets

Rs1.61 Billion

≈ $17.38 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2018–2024)

This chart shows how Bafna Pharmaceuticals Limited's Asset Resilience Ratio has changed over time. Check strategic asset allocation of Bafna Pharmaceuticals Limited to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down Bafna Pharmaceuticals Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Bafna Pharmaceuticals Limited market cap and net worth.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	Rs0.00	0%
Short-term Investments	Rs17.13 Million	1.07%
Total Liquid Assets	Rs17.13 Million	1.07%

Asset Resilience Insights

Limited Liquidity: Bafna Pharmaceuticals Limited maintains only 1.07% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Bafna Pharmaceuticals Limited Industry Peers by Asset Resilience Ratio

Compare Bafna Pharmaceuticals Limited's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Takeda Pharmaceutical Company Limited F:TKDA	Drug Manufacturers - Specialty & Generic	0.69%
Shandong Buchang Pharmaceuticals Co Ltd SHG:603858	Drug Manufacturers - Specialty & Generic	3.47%
Beijing Sun Novo Pharmaceutical Research Co Ltd SHG:688621	Drug Manufacturers - Specialty & Generic	2.04%
Guizhou Xinbang Pharmaceutical Co Ltd SHE:002390	Drug Manufacturers - Specialty & Generic	0.01%
Guangdong Lifestrong Pharmacy Co. Ltd. SHE:301111	Drug Manufacturers - Specialty & Generic	7.85%
Jw Pharmac KO:001060	Drug Manufacturers - Specialty & Generic	3.65%
Kamada TA:KMDA	Drug Manufacturers - Specialty & Generic	0.00%
Samjin Pharm KO:005500	Drug Manufacturers - Specialty & Generic	0.25%

Annual Asset Resilience Ratio for Bafna Pharmaceuticals Limited (2018–2024)

The table below shows the annual Asset Resilience Ratio data for Bafna Pharmaceuticals Limited.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-03-31	0.47%	Rs6.99 Million ≈ $75.63K	Rs1.48 Billion ≈ $15.97 Million	-0.75pp
2021-03-31	1.22%	Rs10.56 Million ≈ $114.21K	Rs864.66 Million ≈ $9.35 Million	-0.93pp
2019-03-31	2.15%	Rs25.74 Million ≈ $278.34K	Rs1.19 Billion ≈ $12.92 Million	+0.38pp
2018-03-31	1.77%	Rs24.50 Million ≈ $264.97K	Rs1.38 Billion ≈ $14.96 Million	--

pp = percentage points

About Bafna Pharmaceuticals Limited

NSE:BAFNAPH India Drug Manufacturers - Specialty & Generic

Market Cap

$68.61 Million

Rs6.34 Billion INR

Market Cap Rank

#20627 Global

#1148 in India

Share Price

Rs268.20

Change (1 day)

+2.01%

52-Week Range

Rs81.38 - Rs268.20

All Time High

Rs507.50